IL1B and leukemia: Our data suggested that the anti-leukemia effect of NF-κB inhibition in vivo can be significantly enhanced by inhibition of either TNF or IL1 signaling alone, and can be further promoted by co-inhibition of both TNF and IL1 signaling (Figure 6).